Center for Digestive and Liver Diseases, Inc.  © 2013  |  Privacy policy

like us

Protocol P11-282


A FDA approved drug for Ulcerative Colitis (Humira) to Evaluate the long term effectiveness of Adalimumab in patients with moderately to severely active UC who have had an inadequate response to conventional therapy


A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)